FY2026 EPS Estimate for Cogent Biosciences Lifted by Analyst

Cogent Biosciences, Inc. (NASDAQ:COGT) – Investment analysts at Leerink Partnrs lifted their FY2026 earnings per share estimates for Cogent Biosciences in a research note issued to investors on Monday, April 28th. Leerink Partnrs analyst A. Berens now anticipates that the technology company will earn ($1.48) per share for the year, up from their previous forecast of ($1.49). The consensus estimate for Cogent Biosciences’ current full-year earnings is ($2.42) per share.

A number of other brokerages have also recently commented on COGT. Wedbush reiterated a “neutral” rating and issued a $11.00 target price on shares of Cogent Biosciences in a research report on Tuesday, February 25th. Scotiabank assumed coverage on Cogent Biosciences in a report on Friday, March 7th. They issued a “sector outperform” rating and a $17.00 price objective on the stock. Needham & Company LLC restated a “hold” rating on shares of Cogent Biosciences in a report on Wednesday, February 26th. Piper Sandler raised Cogent Biosciences to a “strong-buy” rating in a research note on Friday, March 7th. Finally, Robert W. Baird dropped their price objective on Cogent Biosciences from $10.00 to $8.00 and set a “neutral” rating for the company in a research note on Thursday, February 27th. Three research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $14.43.

Cogent Biosciences Stock Performance

COGT stock opened at $5.63 on Thursday. The company has a market capitalization of $641.01 million, a PE ratio of -2.27 and a beta of 1.67. Cogent Biosciences has a one year low of $3.72 and a one year high of $12.61. The company’s 50 day moving average price is $5.88 and its two-hundred day moving average price is $8.04.

Institutional Investors Weigh In On Cogent Biosciences

A number of large investors have recently made changes to their positions in the business. FMR LLC lifted its stake in Cogent Biosciences by 99.2% in the fourth quarter. FMR LLC now owns 16,569,256 shares of the technology company’s stock worth $129,240,000 after acquiring an additional 8,249,845 shares during the period. Vanguard Group Inc. raised its holdings in Cogent Biosciences by 7.3% in the 4th quarter. Vanguard Group Inc. now owns 6,133,380 shares of the technology company’s stock worth $47,840,000 after purchasing an additional 418,975 shares in the last quarter. Paradigm Biocapital Advisors LP lifted its position in shares of Cogent Biosciences by 6.7% in the 4th quarter. Paradigm Biocapital Advisors LP now owns 4,917,412 shares of the technology company’s stock worth $38,356,000 after purchasing an additional 307,650 shares during the period. Adage Capital Partners GP L.L.C. boosted its stake in shares of Cogent Biosciences by 5.8% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 4,300,000 shares of the technology company’s stock valued at $33,540,000 after purchasing an additional 233,966 shares in the last quarter. Finally, Octagon Capital Advisors LP increased its position in shares of Cogent Biosciences by 111.7% during the fourth quarter. Octagon Capital Advisors LP now owns 2,763,000 shares of the technology company’s stock valued at $21,551,000 after buying an additional 1,458,000 shares during the period.

About Cogent Biosciences

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.